Literature DB >> 28855404

Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion.

Janne M Papma1, Lize C Jiskoot2, Jessica L Panman2, Elise G Dopper2, Tom den Heijer2, Laura Donker Kaat2, Yolande A L Pijnenburg2, Lieke H Meeter2, Rick van Minkelen2, Serge A R B Rombouts2, John C van Swieten2.   

Abstract

OBJECTIVE: To investigate cognitive function, gray matter volume, and white matter integrity in the presymptomatic stage of chromosome 9 open reading frame 72 repeat expansion (C9orf72RE).
METHODS: Presymptomatic C9orf72RE carriers (n = 18) and first-degree family members without a pathogenic expansion (healthy controls [HC], n = 15) underwent a standardized protocol of neuropsychological tests, T1-weighted MRI, and diffusion tensor imaging within our cohort study of autosomal dominant frontotemporal dementia (FTD). We investigated group differences in cognitive function, gray matter volume through voxel-based morphometry, and white matter integrity by means of tract-based spatial statistics. We correlated cognitive change with underlying gray or white matter.
RESULTS: Our data demonstrate lower scores on letter fluency, Stroop card I, and Stroop card III, accompanied by white matter integrity loss in tracts connecting the frontal lobe, the thalamic radiation, and tracts associated with motor functioning in presymptomatic C9orf72RE compared with HC. In a subgroup of C9orf72RE carriers above 40 years of age, we found gray matter volume loss in the thalamus, cerebellum, and parietal and temporal cortex. We found no significant relationship between subtle cognitive decline and underlying gray or white matter.
CONCLUSIONS: This study demonstrates that a decline in cognitive functioning, white matter integrity, and gray matter volumes are present in presymptomatic C9orf72RE carriers. These findings suggest that neuropsychological assessment, T1-weighted MRI, and diffusion tensor imaging might be useful to identify early biomarkers in the presymptomatic stage of FTD or amyotrophic lateral sclerosis.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28855404     DOI: 10.1212/WNL.0000000000004393

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

Review 2.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

Review 3.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

4.  Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy.

Authors:  Ignacio Illán-Gala; Victor Montal; Sergi Borrego-Écija; Eduard Vilaplana; Jordi Pegueroles; Daniel Alcolea; Belén Sánchez-Saudinós; Jordi Clarimón; Janina Turón-Sans; Nuria Bargalló; Sofía González-Ortiz; Howard J Rosen; Maria Luisa Gorno-Tempini; Bruce L Miller; Albert Lladó; Ricard Rojas-García; Rafael Blesa; Raquel Sánchez-Valle; Alberto Lleó; Juan Fortea
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

Review 5.  Pre-symptomatic radiological changes in frontotemporal dementia: propagation characteristics, predictive value and implications for clinical trials.

Authors:  Mary Clare McKenna; Jasmin Lope; Ee Ling Tan; Peter Bede
Journal:  Brain Imaging Behav       Date:  2022-08-03       Impact factor: 3.224

Review 6.  Cerebellar pathology in motor neuron disease: neuroplasticity and neurodegeneration.

Authors:  Rangariroyashe H Chipika; Grainne Mulkerrin; Pierre-François Pradat; Aizuri Murad; Fabrice Ango; Cédric Raoul; Peter Bede
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

Review 7.  The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?

Authors:  Rangariroyashe H Chipika; We Fong Siah; Mary Clare McKenna; Stacey Li Hi Shing; Orla Hardiman; Peter Bede
Journal:  J Neurol       Date:  2020-10-31       Impact factor: 6.682

Review 8.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

Review 9.  Cognitive dysfunction in amyotrophic lateral sclerosis: can we predict it?

Authors:  Fabiola De Marchi; Claudia Carrarini; Antonio De Martino; Luca Diamanti; Antonio Fasano; Antonino Lupica; Mirella Russo; Simone Salemme; Edoardo Gioele Spinelli; Alessandro Bombaci
Journal:  Neurol Sci       Date:  2021-03-27       Impact factor: 3.307

10.  MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.

Authors:  Ziqiang Lin; Eugene Kim; Mohi Ahmed; Gang Han; Camilla Simmons; Yushi Redhead; Jack Bartlett; Luis Emiliano Pena Altamira; Isobel Callaghan; Matthew A White; Nisha Singh; Stephen Sawiak; Tara Spires-Jones; Anthony C Vernon; Michael P Coleman; Jeremy Green; Christopher Henstridge; Jeffrey S Davies; Diana Cash; Jemeen Sreedharan
Journal:  Brain Commun       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.